by [email protected] | Nov 26, 2024 | MYNZ
A Balanced Analysis of Mainz Biomed N.V. (NASDAQ: MYNZ) Mainz Biomed N.V. (MYNZ) has garnered attention for its innovative approach to early cancer detection. Its flagship product, ColoAlert, a non-invasive stool-based test for colorectal cancer, and the...